AstraZeneca PLC and Exelixis, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: AstraZeneca vs. Exelixis

In the competitive landscape of the pharmaceutical industry, understanding spending patterns is crucial. Over the past decade, AstraZeneca PLC and Exelixis, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. AstraZeneca, a global leader, has consistently invested heavily in SG&A, with a notable 35% increase from 2014 to 2023. This reflects their expansive market strategies and robust operational scale. In contrast, Exelixis, a smaller biotech firm, has seen a staggering 967% rise in SG&A expenses over the same period, indicating aggressive growth and expansion efforts. While AstraZeneca's spending dwarfs Exelixis in absolute terms, the latter's rapid increase highlights its dynamic approach to scaling operations. These trends underscore the diverse strategies employed by pharmaceutical giants and emerging biotech firms in navigating market challenges and opportunities.

Key Insights

• AstraZeneca's SG&A expenses grew by 35% from 2014 to 2023.
• Exelixis experienced a 967% increase in SG&A spending, reflecting its growth ambitions.